Advancing Fully Open Access OpenDEL as a Self serve DEL Kit

Chemspace & Hitgen Webinar 'Advancing Fully Open Access: OpenDEL as a Self-serve DNA-Encoded Library Kit Benefits Your Drug Discovery Research'.
The Speaker is Dr. Guansai Liu, Vice President at Hitgen Inc. Hosted by Dr. Olga Tarkhanova.
Although DNA-encoded libraries (DELs) have increasingly been recognized as a powerful technical tool for hit identifications, few companies and research institutions around the world have built their own DEL platforms in-house for drug discovery research, due to high initial investing expense on library construction and multi-discipline capability building. HitGen’s OpenDEL is a self-serve DEL kit to enable researchers to explore DEL selection campaigns using their own deep insights on biological targets.
Key features of OpenDEL include, but are not limited to:
1. Fully open access: all compound and codon information of 2 billion of compounds is open to users.
2. Target-blinded: No need to disclose biological target information.
3. Enabling: selection manual and key materials are provided to enable users to run selection experiments in-house.
4. No cost for licensing: no license fee when compounds are identified.
5. Drug-likeness: no 4-cycle DELs; 90% encoded molecules give MW less than 550 Dalton.
6. Diversity: ~20,000 building blocks are used in DELs; novel chemistries are applied.
#Chemspace #HitGen #DEL #OpenDEL
0:00 Chemspace introduction by Chief Sales Officer Dr. Olga Tarkhanova:
- CS business activities
- Exploration of Giga-scale chemical spaces
- V-SYNTHES approach
- Crystal structure first approach
- DEL-ML approach
4:40 Speaker’s introduction: Dr. Guansai Liu, Vice President at HitGen Inc.
7:07 Intro
7:43 Outline of the presentation
7:56 DEL: key invention and development
9:20 Brief introduction to DEL
10:41 Classical DEL selection for novel hit identification
12:05 Advantages of DEL technology
12:32 Example hits identified via DEL screening
13:14 Novel inhibitor discovery for NAA50
14:30 Novel GPCR inhibitor discovery
15:25 Novel inhibitor discovery for IL-17A/IL-17R
16:11 Novel inhibitor discovery for transcription factor
16:49 Challenging PPI PROTAC discovery with completely novel POI ligand
17:30 Novel CRBN binders for potent POI degradation
18:17 DEL selection data for SAR and SSR study
19:36 DEL selection data for Machine Learning (ML)
20:55 Big investments on building DEL platforms
21:42 DELs of Your own: “OpenDEL - Billions in a Vial!”
22:29 Introduction of OpenDEL. Description of product
23:58 Qualities of OpenDEL molecules: 1. Library Design
24:23 Novel chemistry used in OpenDEL:
- C3-Alkylations of Indoles
- Indazolone formation
28:16 Qualities of OpenDEL molecules: 2. Molecular Diversity
- More than 20 000 BBs used in OpenDEL
- Molecular shape diversity of OpenDEL
- 30 independent DELs, 56 generic structures!
32:32 Qualities of OpenDEL molecules: 3. Molecule Druglikeness
- Properties of DEL molecules
33:21 Workflow of OpenDEL
34:59 Customer experiences
35:55 HitGen contacts for OpenDEL 3.0 purchasing
36:22 About HitGen Inc.
37:16 HitGen innovative Drug Discovery research platform
39:20 DEL publications by HitGen
39:45 HitGen collaboration partners
40:26 Welcome to visit HitGen!
40:45 Q&A session

[@kennymccoy949]

🎶 "Promosm"